📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Dr. Agarwal's Health Care Receives ICRA AA- (Stable) Rating for ₹200 Cr Debt Facilities
ICRA Limited has reaffirmed the long-term credit rating of 'ICRA AA- (Stable)' for Dr. Agarwal's Health Care Limited's debt facilities. The rating covers ₹73.80 crores in outstanding long-term loans and ₹126.20 crores in unallocated limits. Additionally, a short-term rating of 'ICRA A1+' was assigned/reaffirmed for the enhanced unallocated amount. This high-grade rating reflects the company's strong creditworthiness and stable financial outlook.
Key Highlights
ICRA reaffirmed 'ICRA AA- (Stable)' rating for ₹73.80 crores in long-term bank loans from HDFC, YES, and ICICI Bank
Assigned and reaffirmed 'ICRA AA- (Stable)' and 'ICRA A1+' ratings for ₹126.20 crores of unallocated limits
Total bank facilities covered under the rating action amount to ₹200 crores
The 'Stable' outlook indicates expected steady operational performance and financial stability
💼 Action for Investors
Investors should take confidence in the company's high credit rating, which suggests low default risk and access to competitive borrowing rates. No immediate action is required as this reaffirms the company's solid financial footing.
Dr. Agarwal's Health Care Receives Stock Exchange Clearance for Merger with AEHL
Dr. Agarwal's Health Care Limited (AHCL) has received 'no objection' from NSE and 'no adverse observations' from BSE for its proposed merger with Dr. Agarwal's Eye Hospital Limited (AEHL). This regulatory clearance, following the board's August 2025 approval, allows the company to proceed with filing the scheme before the National Company Law Tribunal (NCLT). The company must now provide detailed disclosures to shareholders, including a cost-benefit analysis and a 3-year financial track record of both entities. The observation letters are valid for six months, requiring the NCLT filing to be completed by August 2026.
Key Highlights
Received 'No Objection' from NSE on Feb 16, 2026, and 'No Adverse Observations' from BSE on Feb 17, 2026
The scheme involves the amalgamation of Dr. Agarwal's Eye Hospital Limited (AEHL) into Dr. Agarwal's Health Care Limited (AHCL)
Observation letters are valid for 6 months, setting a deadline for NCLT filing by August 2026
SEBI mandates disclosure of 3-year Revenue, PAT, and EBITDA for both entities in the explanatory statement to shareholders
Company required to justify the rationale for the merger occurring shortly after the listing of AHCL
💼 Action for Investors
Investors should look forward to the detailed explanatory statement which will reveal the share-swap ratio and projected synergies. Monitor the NCLT approval process as the next major milestone for the consolidation.
Dr. Agarwal's Health Care Q3 PAT Jumps 55% YoY to ₹44 Cr; Revenue Up 23%
Dr. Agarwal's Health Care reported a robust Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore. Net profit for the quarter surged 55% YoY to ₹44 crore, driven by a higher mix of complex surgeries and improved operational efficiencies. The company expanded its network to 253 facilities, adding 14 new centers in Q3 alone, with plans to add 16 more in Q4. EBITDA margins remained strong at 28.4%, supported by a 25% increase in daily patient walk-ins to approximately 10,000.
Key Highlights
Q3 FY26 PAT grew 55% YoY to ₹44 crore with margins expanding by 171 bps to 8.1%
Total network expanded to 253 facilities across 148 cities, with 14 new centers added in Q3 FY26
Robotic cataract surgeries (Femto) saw a massive 83% YoY growth, reflecting a shift toward high-value procedures
9M FY26 EBITDA stood at ₹440 crore, up 23.6% YoY with a healthy margin of 28.4%
Surgical services remain the primary revenue driver, contributing 67% to the total group revenue
💼 Action for Investors
Investors should note the strong volume growth and margin expansion as a sign of successful scaling and premiumization. The aggressive expansion into North and West India provides a long-term growth runway that warrants a positive outlook.
Dr. Agarwal's Health Care Q3 FY26: PAT Surges 74.3% YoY to ₹118 Cr; Total Income Up 20.8%
Dr. Agarwal's Health Care reported a strong financial performance for 9M FY2026, with total income growing 20.8% YoY to ₹1,548 crore. Profit After Tax (PAT) saw a significant jump of 74.3% YoY, reaching ₹118 crore, driven by improved margins and operational efficiencies. The company expanded its network to 272 facilities, adding 38 new centers during the first nine months of the fiscal year. With a robust pipeline of 16 more facilities planned for Q4 FY26, the company continues its aggressive expansion strategy across India and international markets.
Key Highlights
Total Income grew 20.8% YoY to ₹1,548 Cr for 9M FY26, with EBITDA margins improving to 28.4%.
PAT increased by 74.3% YoY to ₹118 Cr, reflecting significant operational leverage.
Network expanded to 272 facilities across 10 countries, with 38 new additions in the first nine months.
Surgery volumes increased by 11.6% YoY to 238K+, contributing 67% of total revenue mix.
Aggressive expansion remains on track with 16 new facilities planned for launch in Q4 FY26.
💼 Action for Investors
Investors should take note of the strong margin expansion and rapid network growth as the company scales its presence. The significant growth in PAT and surgery volumes suggests strong brand equity and operational efficiency, making it a positive outlook for long-term growth.
Dr. Agarwal's Health Care 9M PAT Jumps 74.3% to ₹118 Cr; Expands to Ethiopia
Dr. Agarwal's Health Care Limited reported a robust financial performance for 9M FY26, with Profit After Tax (PAT) surging 74.3% YoY to ₹118 Crores. Total income grew by 20.8% to ₹1,548 Crores, supported by the addition of 38 new centers, bringing the total network to 272 facilities across 10 countries. The company also announced the incorporation of a new subsidiary in Ethiopia and the cessation of Idearx Services as an associate company, while maintaining a 14.54% equity stake.
Key Highlights
9M FY26 PAT increased by 74.3% YoY to ₹118 Crores; Q3 FY26 PAT grew 54.5% to ₹44 Crores
Total Income for 9M FY26 rose 20.8% YoY to ₹1,548 Crores, driven by healthy patient volumes
Network expanded to 272 facilities with 38 new centers added in the first nine months of FY26
EBITDA for 9M FY26 grew 23.6% YoY to ₹440 Crores with margins improving to 28.4%
Performed 238,283 surgeries in 9M FY26, representing an 11.6% growth compared to the previous year
💼 Action for Investors
Investors should view the strong earnings growth and aggressive network expansion positively. Monitor the performance of the new Ethiopian subsidiary and the impact of the 'hub and spoke' model on future margins.
Dr. Agarwal's Q3 PAT Surges 54.5% to ₹44 Cr; Revenue Up 23% YoY
Dr. Agarwal's Health Care reported a robust Q3 FY26 with revenue from operations growing 23% YoY to ₹530 crore, driven by healthy patient volumes and mature facility performance. Profit After Tax (PAT) witnessed a significant jump of 54.5% YoY to ₹44 crore, while 9M FY26 PAT soared 74.3% to ₹118 crore. The company continued its aggressive expansion, adding 14 new centers in Q3 to reach a total network of 272 facilities. Additionally, the board approved a new subsidiary in Ethiopia and the reclassification of Idearx from an associate to a regular investment.
Key Highlights
Q3 FY26 Total Income grew 21.9% YoY to ₹540 crore; 9M FY26 income reached ₹1,548 crore.
EBITDA for Q3 FY26 increased by 21.3% YoY to ₹155 crore with a healthy margin of 28.6%.
Surgery volumes rose 11.2% YoY to 81,002 in Q3; total surgeries for 9M FY26 reached 238,283.
Revenue from mature facilities grew by 37.8% YoY, indicating strong organic growth in established centers.
Network expanded to 272 facilities across 10 countries, with 38 centers added in the first nine months of FY26.
💼 Action for Investors
The company's strong earnings growth and successful hub-and-spoke model expansion suggest a positive outlook. Investors should monitor the ramp-up of the 38 newly added centers and the progress of international expansion in Ethiopia.